Keyword Connections

moxifloxacin

Journals

0

No Journal Connected

Research Groups

0

No Research Group Connected

Bibliographies

13

1 Apparent failure of moxifloxacin to prevent ciprofloxacin- and levofloxacin-susceptible Pseudomonas aeruginosa bacteremia in neutropenic patients undergoing peripheral blood stem cell transplantation

2 Chemical synthesis of chitosan/silver nanocomposites films loaded with moxifloxacin: Their characterization and potential antibacterial activity.

3 Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains

4 Preparation, in vitro release and antibacterial activity evaluation of rifampicin and moxifloxacin-loaded poly(D,L-lactide-co-glycolide) microspheres

5 Design, synthesis and antibacterial activity evaluation of moxifloxacin-amide-1,2,3-triazole-isatin hybrids

6 Stimuli Responsive In Situ Gelling Systems Loaded with PLGA Nanoparticles of Moxifloxacin Hydrochloride for Effective Treatment of Periodontitis.

7 High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.

8 4-month moxifloxacin containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis in South India - a randomised clinical trial.

9 Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge

10 effects of moxifloxacin on the proarrhythmic surrogate markers in healthy filipino subjects: exposure-response modeling using ecg data of thorough qt/qtc study

11 validated microbiological and hplc methods for the determination of moxifloxacin in pharmaceutical preparations and human plasma

12 effects of moxifloxacin on human neutrophil and t-lymphocyte functions in vitro

13 Treatment with Sequential Intravenous or Oral Moxifloxacin Was Associated with Faster Clinical Improvement than Was Standard Therapy for Hospitalized Patients with Community-Acquired Pneumonia Who Received Initial Parenteral Therapy